Press Release from the Competition Council regarding the economic concentration project concerning the acquisition by the company “Hikma Mena FZE” of the exclusive control of certain rights and assets held by the company “Takeda Pharmaceutical International AG.”

In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation, as amended and supplemented, the Competition Council makes available to the public the “operation summary” below, containing the information provided by the parties.

This information has been prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed operation.

The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law No. 104-12 on freedom of prices and competition as amended and supplemented.

Names of companies and individuals involved:

• The acquirer: “Hikma Mena FZE”;
• The target: Certain rights and assets held by the company “Takeda Pharmaceutical International AG”

Nature of the operation:

• Exclusive control acquisition.

Economic sector concerned:

• Pharmaceutical industry sector.

Deadline for interested third parties to submit their observations:

• 10 days from the date of publication of this press release, i.e. February 26, 2025.

NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES

The Competition Council has received notification of an economic concentration project concerning the acquisition by the company “Hikma Mena FZE” of the exclusive control of certain rights and assets held by the company “Takeda Pharmaceutical International AG.”

“Hikma Mena FZE” is a limited liability company based in Dubai, a wholly-owned subsidiary of “Hikma Pharmaceuticals PLC,” which manufactures specialized generic and branded pharmaceutical products across North America, the MENA region, North Africa, and Europe.

“Takeda Pharmaceutical International AG” is a Swiss public limited company, a subsidiary of “Takeda Pharmaceutical Company Limited,” engaged in research, development, and commercialization of innovative drugs in key therapeutic areas such as gastroenterology, oncology, rare diseases, and neuroscience.

 

Done in Rabat, February 13, 2025